NEW YORK, May 14, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of drugs to fight biowarfare pathogens, today announced that on May 11, 2009, it submitted its response to the Biomedical Advance Research and Development Authority (BARDA) regarding the agency’s outstanding RFP for the procurement of 1.7 million courses of a smallpox antiviral.
